S&P 500 ends at seven-month high after Yellen comments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches up on megacap strength; Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar rises to session high after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
AbbVie (ABBV) Announces Additional Data on IMBRUVICA Phase 3 in CLL/SLL
June 6, 2016 9:03 AM EDTAbbVie (NYSE: ABBV) announced longer-term follow-up results from Phase 3 studies of IMBRUVICA (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Findings include an analysis of outcomes from the RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115) trials, which showed IMBRUVICA was associated with favorable progression-free survival (PFS) and overall survival (OS) regardless of line of therapy (previously treated or treatment-naïve; abstract 7520). Other data include first-ever presentation of longer-term follow-up data from the HELIOS (CLL3001) trial showing... More
Cowen Remains Sidelined on Wal-Mart (WMT) After Spending Time with Management
June 6, 2016 8:18 AM EDTCowen maintained a Market Perform rating and $70.00 price target on Wal-Mart (NYSE: WMT) after spending time with senior leadership. CEO Doug McMillion is leading WMT on path to deliver a seamless shopping experience through multi-format stores, easy pickup, fast delivery, and apps/... More
